Mito Health Hits 1 Million Lab Tests — and the $9 Membership Model Is Why It Matters
Mito Health, the direct-to-consumer diagnostics platform, has processed over 1 million lab tests at cost with a $9/month flat-fee membership. The milestone marks a shift in how serious longevity practitioners access biomarker data — no insurance, no referrals, no per-test markup.
Blood Pressure and Longevity: What Peter Attia's AMA #48 Gets Right About Measurement
Blood pressure is one of three primary drivers of atherosclerosis — yet most people check it once a year. Attia's AMA #48 rebroadcast makes the case for treating it as a daily metric.
Zone 2 Training: Why Time-Constrained Athletes May Be Better Off Skipping It
Peter Attia reframes Zone 2 as a volume tool, not a metabolic must-do — and the implications for busy people are bigger than expected.
Insilico Medicine's 287% Revenue Jump: AI Drug Discovery Is Becoming Real Pharma Revenue
Insilico Medicine grew to $106M revenue in H1 2026 on $7.3B in total deal value with Eli Lilly, Servier, and others — and a 90% gross margin that confirms AI drug pipelines have crossed from research promise to commercial scale.
Oura Health Files for IPO at $16 Billion: What a Smart Ring's Valuation Tells Us About Biometric Data
Oura Health is targeting a $3B raise at a $16B valuation — a 45% jump from 18 months ago — built on a hardware-plus-subscription model that turns sleep and recovery data into recurring revenue.
Mount Sinai's $1M XPRIZE Bet: Can the Immune System Be Reset to Fight Aging?
Mount Sinai secured $1M in XPRIZE Healthspan funding to run NYC-Vita, a trial combining lifestyle and medication to restore immune function decades lost to aging.
Quest Diagnostics Is Now Selling Biological Age: What the $29 Test Actually Measures
Humanity's biological age test is now a $29 add-on at 2,000 Quest locations. The model behind it tracked 306,000+ people for 11.6 years and covers six body systems.
KardiaMobile 6L: The Study That Found Twice as Many Arrhythmias as Hospital Monitors
A University of Rochester cohort study published in JACC Advances found AliveCor's KardiaMobile 6L detected nearly twice the arrhythmia rate of traditional short-duration ECG monitors in 350 patients over 30 days.
Gum Recession: Why the Habits You Think Are Helping May Be Hurting
Gum recession affects 88% of adults 65+, and aggressive brushing is a leading cause. Why lost gum tissue never grows back — and the one technique change that matters.
Tru Niagen at GNC and Sam's Club Signals NAD+ Has Left the Longevity Niche
The number one NAD+ supplement in the US is now in nearly 300 retail locations across 44 states. What the GNC and Sam's Club expansion says about where the longevity market is heading.
Whole-Body MRI Is Leaving the Biohacker Bubble
EHE Health's partnership with Prenuvo brings whole-body MRI screening into 200+ preventive care clinics. What this transition from biohacker niche to medical infrastructure means for longevity-minded members.
Wonderfeel: What a 4,235% Growth Rate Signals for the NAD+ Supplement Market
The NAD+ longevity brand ranked No. 1 biotech on the 2026 Inc. 5000. The growth rate reflects a consumer longevity market that's moving faster than most industry observers expected.
Can AI Put the Cell Back Together? GenBio's Virtual Cell Model Tries
GenBio AI's AIDO Cell system creates a stateful virtual cell model — integrating DNA, RNA, and protein behavior — to predict how intervention sequences affect biological aging.
Function Health's AI Connector: Your Lab Results Just Became AI Training Data — For You
Function's new connector links 160+ personal lab results to ChatGPT, Claude, and Perplexity. Over 80% of members have at least one biomarker outside optimal range — now AI can reason over that directly.
GDF-15 and P-Tau217: The Biomarkers That Warn You Before You Feel Anything
New biomarker research is shifting the question from 'what's wrong?' to 'what's coming?' GDF-15 as a cellular stress signal and p-tau217 for pre-symptomatic Alzheimer's risk represent a new category of early detection — but their limitations matter as much as their promise.
Biological Age Clocks: The Regulatory Reckoning Is Coming
With $3.74 billion flowing into longevity biotech in Q1 2026 alone, investors are backing biological age diagnostics that regulators cannot yet validate. The collision between capital and clinical evidence is building.
GDF-15 and P-tau217: The Biomarkers That Signal Breakdown Before You Feel It
Two biomarkers — GDF-15 for cellular stress and P-tau217 for Alzheimer's risk — can flag physiological strain years before symptoms appear. Here's what they measure, what trends reveal, and why a single reading misses the point.
Peter Attia Episode 404: Why the Neurotransmitter Model of Mental Health Is Incomplete
Dr. Linus Abrams argues that psychiatry's focus on symptom reduction through medication overlooks the hormonal, metabolic, and inflammatory drivers of mental health. The implications for how practitioners and patients think about mental wellbeing are significant.
The Antiaging Trial That Just Won $1M From XPRIZE to Test in Humans
AgelessRx has been selected as one of 10 Milestone 2 awardees in the $101M XPRIZE Healthspan competition, earning $1M to advance a one-year randomized trial testing a six-component antiaging protocol including low-dose rapamycin, NAD+, and metformin.
Menopause Is a Muscle-Health Inflection Point — and Most Programs Miss It
Estrogen decline during menopause narrows the window for muscle protein synthesis and changes how training responds. The intervention stack is specific: protein distribution, progressive resistance, and individualized HRT consideration — not just more of each.
5 Perimenopause Supplements That Actually Hold Up: Evidence-Graded and Label-Checked
Most perimenopause supplement blends are under-dosed marketing. This evidence-graded breakdown identifies five options that hold up on clinical data, labeled doses, and standardized extracts.
5 Perimenopause Supplements That Hold Up: Evidence-Graded and Label-Checked
Most perimenopause supplement blends are underdosed and opaque. This evidence-graded breakdown applies clinical trial dosing standards to the current field — here are the five that survive scrutiny.
Blood Filtering Is the New Wellness Flex — And Viome Just Bought the Infrastructure
Viome's acquisition of Circulate Health pairs multi-omics biomarker testing with therapeutic plasma exchange. What this convergence means for longevity-focused consumers navigating an increasingly clinical wellness stack.
Peptides: Peter Attia's Framework for Separating Science from Marketing
Peter Attia's episode #403 gives biohackers a rigorous 5-question test for evaluating peptides — and most gray-market compounds fail at question one.